Cargando…
Medicalising short children with growth hormone? Ethical considerations of the underlying sociocultural aspects
In 2003, the Food and Drug Administration approved the use of growth hormone treatment for idiopathic short stature children, i.e. children shorter than average due to an unknown medical cause. Given the absence of any pathological conditions, this decision has been contested as a case of medicalisa...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956020/ https://www.ncbi.nlm.nih.gov/pubmed/28852938 http://dx.doi.org/10.1007/s11019-017-9798-6 |